Cancer Cell Diagnostics Launches CellSight™ DNA Comprehensive Genomic Profiling Test to Advance Precision Oncology Cancer Cell Diagnostics (CCDx) has announced the commercial launch of CellSight™ DNA, its next-generation comprehensive genomic profiling (CGP) assay designed to provide oncologists with a broader…
Seek Labs Publishes Nature Communications Study Showcasing ANINA™ Technology for Next-Generation Molecular Diagnostics Seek Labs, a private TechBio company focused on developing programmable technologies to decode, understand, and treat disease, has announced the publication of a peer-reviewed research paper in…
FUJIFILM Sonosite Launches Sonosite iLOOK, a Dedicated Ultrasound Solution Designed to Enhance Vascular Access Procedures FUJIFILM Sonosite, Inc., a global leader in point-of-care ultrasound (POCUS) technology, has announced the introduction of Sonosite iLOOK, a compact ultrasound solution specifically engineered to…
Kinaset Therapeutics Doses First Patient in Phase 2b Trial of Frevecitinib for Severe Asthma Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative inhaled therapies for serious respiratory diseases, has announced the dosing of the first patient in its…
iVeena Delivery Systems Completes Phase 1 Trial of IVMED-85, Advancing Novel Eye Drop Therapy for Pediatric Myopia iVeena Delivery Systems, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing innovative therapies for eye diseases, has announced the successful completion of…
Veradermics Presents New Phase 2/3 Data Highlighting the Potential of VDPHL01 for Male Pattern Hair Loss Across Age Groups Veradermics, Incorporated, a late-stage biopharmaceutical company founded by dermatologists and dedicated to developing innovative therapies for pattern hair loss, has announced…
TruTechnologies Unveils New Brand Identity as It Advances Real-Time Clinical Trial Innovation TruTechnologies, a clinical trial software company specializing in real-time visibility into trial execution at the point of care, has introduced a refreshed corporate brand identity alongside the launch…
Kairos Pharma Reports Encouraging Phase 1 Safety Results for ENV-105 Combined with Osimertinib in EGFR-Mutated Lung Cancer Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing therapies to overcome drug resistance in cancer, has announced encouraging interim safety results…
Incyte Presents Positive Phase 1/2 Data for Latarcibart in Von Willebrand Disease, Supporting Ongoing Phase 3 Development Incyte has announced comprehensive safety and efficacy results from its Phase 1/2 multidose clinical study evaluating VGA039 (latarcibart), an investigational monoclonal antibody designed…
Meridian Bioscience Receives Health Canada Approval for Alethia® CMV Assay, Expanding Molecular Diagnostics Portfolio Meridian Bioscience, Inc., a global provider of diagnostic testing solutions and life science raw materials, has announced that Health Canada has granted a medical device license…
Ionis and Biogen Report Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease, Supporting Advancement to Phase 3 Ionis Pharmaceuticals, Inc. has announced that its long-standing collaboration partner, Biogen, presented new data from the Phase 2 CELIA clinical trial…
CEL-SCI Launches Global Confirmatory Registration Study of Multikine® for Newly Diagnosed Head and Neck Cancer CEL-SCI Corporation has announced the initiation of its global Confirmatory Registration Study evaluating Multikine® (Leukocyte Interleukin, Injection) as a neoadjuvant immunotherapy for patients with newly…